Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2137696 | Leukemia Research | 2010 | 8 Pages |
Abstract
Histone deacetylase (HDAC) inhibitors have been shown to induce cell cycle arrest, terminal differentiation, and apoptosis in a broad spectrum of human tumors and animal xenograft models. JNJ-26481585 is a hydroxamic acid derivative, second-generation pan-HDAC inhibitor that has demonstrated high potency in preclinical studies. In the current study, we demonstrated that JNJ-26481585 has antileukemia and molecular activity in leukemia cell lines and primary human leukemia cells. We also observed a synergistic effect between treatment with decitabine and JNJ-26481585. In conclusion, JNJ-26481585 is a potent second-generation pan-HDAC inhibitor with activity in human leukemia, and it is currently in clinical development.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Wei-Gang Tong, Yue Wei, William Stevenson, Shao-Qing Kuang, Zhihong Fang, Ming Zhang, Janine Arts, Guillermo Garcia-Manero,